Zenosense Inc. ZENO Archives - Page 3 of 4

MondayApr 30, 2018 12:21 pm

Zenosense, Inc. (ZENO) Developing Handheld Diagnostic Device for Cardiac Emergency Triage

Every 43 seconds, someone in the U.S. has a heart attack Over six million patients visit U.S. emergency rooms reporting chest pain each year Chest pain symptoms can be hard to diagnose in emergencies but are vital to assessing for heart attack Zenosense’s handheld device aims to give first responders rapid, highly sensitive analysis of heart biomarkers Each year, well over six million patients visit emergency rooms across the United States reporting chest pain. Most of these patients are not suffering from an acute myocardial infarction (AMI/heart attack), but they are a major burden on emergency departments, with billions of…

FridayApr 27, 2018 10:07 am

QualityStocksNewsBreaks – Zenosense, Inc. (ZENO) Targets Global POC Market with MIDS Cardiac Device

Healthcare technology company Zenosense (OTC: ZENO) is well positioned to capitalize on the projected growth in the global point-of-care (“POC”) diagnostics market, forecast to grow at a CAGR of 10 percent, from $23.71 billion in 2017 to $38.13 billion in 2022 according to a recent Research and Markets report (http://ibn.fm/WEs57), through the development and commercialization of its MIDS Cardiac device. An article discussing the company reads: “MIDS’ key differentiator is its unique ability to detect and measure these assay beads by their total aggregated nano-magnetic signal, rather than conventional optical detection. Initial testing has demonstrated that this novel approach should…

ThursdayApr 26, 2018 11:49 am

Zenosense, Inc. (ZENO) Developing Game Changing Medical Nano-Magnetic Diagnostic Technology

Global Point Of Care (POC) diagnostics market projected to grow from $23.71 billion in 2017 to $38.13 billion in 2022 Patented diagnostic technology for POC devices Initial development of MIDS Cardiac™, a POC device for early and rapid cardiac biomarker detection Global cardiac biomarkers market expected to reach $13.3 billion by 2024 Delivering MIDS Cardiac™ would allow the technology to be applied to multiple other immunoassay tests with a global market that’s projected to be worth $25.45 billion by 2021 The global point-of-care (POC) diagnostics market is forecast to grow at a CAGR of 10 percent, from $23.71 billion in…

FridayApr 13, 2018 3:42 pm

QualityStocksNewsBreaks – Zenosense, Inc. (ZENO) Focuses on Development, Commercialization of Handheld POC Diagnostic Device to Rapidly Detect Heart Attack

Healthcare technology company Zenosense (OTC: ZENO) is primarily focused on the development and commercialization of MIDS Cardiac™ through the company’s joint venture ownership in MIDS Medical Limited (“MML”). An article discussing the company reads: “True, high-sensitivity devices are not available in smaller handheld devices at the POC, where they are most needed. This is because the optical detection systems generally used in central laboratory analyzers cannot be effectively miniaturized. … MIDS Cardiac uses the patented MIDS technology platform, exclusively available to MML. Instead of using conventional optical detection, MIDS can detect and quantify assay beads nano-magnetically. This means it can…

MondayApr 09, 2018 11:02 am

Zenosense, Inc. (ZENO) is “One to Watch”

Global biomarker diagnostic testing market projected to reach $53.34 billion by 2021 from $27.95 billion in 2016 Zenosense’s device development incorporates key technology which is patent protected Technology platform could be used to test for a wide variety of common medical conditions that typically are undertaken in laboratory setting at huge expense Point of Care / rapid diagnostics market expected to reach $38.13 billion by 2022 Zenosense, Inc. (OTC: ZENO) is a healthcare technology developer that participates in transformational, disruptive medical diagnostic projects; particularly handheld devices used at the Point of Care which are displacing slow and expensive laboratory tests.…

WednesdayJun 25, 2014 12:00 pm

Zenosense, Inc. (ZENO): Possessing Strong Growth Opportunity with MRSA Detector

Zenosense, a healthcare technology company, is focusing on developing a novel device to detect the Methicillin-resistant Staphylococcus aureus (MRSA) "Super-Bug" frequently found in the human respiratory tract and on the skin. The company with its advance sensory technology is developing more efficient MRSA detectors that act like smoke alarms. This will enable it to grab the demands from hospitals for detecting health-associated infections (HAIs). The MRSA-detecting device gives Zenosense a greater growth opportunity, as, according to CDC estimates, one out of every 20 hospitalized patients in the U.S. can be infected with HAI, and the annual cost of treating hospitalized…

TuesdayJun 17, 2014 4:46 pm

Zenosense, Inc. (ZENO) Centered on Developing Detection Device to Ward-Off MRSA Cell Activity

Zenosense is looking at developing and marketing a device to be used in healthcare settings to detect the Methicillin-resistant Staphylococcus aureus (MRSA) “Super-Bug.” The company’s findings are grabbing the attention of the medical community as noted in many reputable publications. ScienceDaily, reporting on an article in The New England Journal of Medicine about a new highly-resistant MRSA bacterium, stated University of Texas Health Science Center’s international research team has identified a new superbug which has caused an infection in the bloodstream in a patient in Brazil. This case is the first reported bloodstream infection caused by a highly vancomycin-resistant MRSA…

TuesdayJun 10, 2014 3:38 pm

Zenosense, Inc. (ZENO) Combating MRSA Superbug with Effective Detection/Sensor Technology

Zenosense is hammering out the technical details for their MRSA/MSSA (Methicillin-Resistant/Sensitive Staphylococcus aureus, or staph, infection) detection device designed to offset the primary component of contraction rates, Healthcare-Associated Infections (HAIs), with a comprehensive monitoring/sensor technology that can differentiate S. areus-specific signature VOCs (volatile organic compounds) from background VOCs. A recent status report update on developmental work done on the device, in conjunction with the company's partner and European sensor specialists, Sgenia Group, gives positive indications that a technological solution to effective detection/monitoring of MRSA is right around the corner. Great news for hospitals, the overwhelming majority source for MRSA infections,…

TuesdayJun 03, 2014 1:34 pm

Zenosense, Inc. (ZENO) Pursues MRSA Detection Device to Combat Cell Pervasiveness

Healthcare technology company, Zenosense, with an eye on developing and bringing to market a device for use in hospitals to detect the Methicillin-resistant Staphylococcus aureus (MRSA) “Super-Bug,” is flagging numerous published media articles of late regarding MRSA and Super-Bugs. ScienceDaily, reporting on an article in The New England Journal of Medicine about a new highly-resistant MRSA bacterium, stated University of Texas Health Science Center’s international research team has identified a new superbug which has caused a bloodstream infection in a patient in Brazil. This case is the first reported bloodstream infection caused by a highly vancomycin-resistant MRSA bacteria. Vancomycin [vang-kuh-mahy-sin]…

TuesdayMay 27, 2014 9:40 am

Zenosense, Inc. (ZENO) Cites Recent Media Attention Supporting Need for its MRSA Detector

Zenosense, a healthcare technology company with a focus on developing and marketing a device for use in healthcare settings to detect the Methicillin-resistant Staphylococcus aureus (MRSA) "Super-Bug," acknowledges a several recent and relevant articles in the media regarding MRSA and Super-Bugs. One such recent report comes from CBS News in which they cite a study showing MRSA is taking up residence in people's homes as well as healthcare settings: According to the lead researcher at Columbia University Medical Center, MRSA is now endemic in households. The findings were published on April 21, 2014 in Proceedings of the National Academy of…

Site Search

Company Search

Tag: Zenosense Inc. ZENO